Supernus Pharmaceuticals (SUPN) Accumulated Expenses (2011 - 2026)
Supernus Pharmaceuticals (SUPN) posted quarterly Accumulated Expenses of $198.8 million for Q2 2026, up 9.91% year-over-year from $180.9 million in Q2 2025, and up 4.81% on a QoQ basis from $189.7 million in Q1 2026.
Supernus Pharmaceuticals (SUPN) Accumulated Expenses (2011 - 2026) Analysis & Trends
Supernus Pharmaceuticals has reported Accumulated Expenses for 16 years, with the latest figure at $198.8 million in Q2 2026.
- Accumulated Expenses for Q2 2026 came in at $198.8 million, up 9.91% year-over-year; the trailing twelve-month figure through Jun 2026 was $198.8 million (up 9.91% YoY), and the FY2025 annual result was $161.1 million, down 4.51% from the prior year.
- Accumulated Expenses rose to $198.8 million in Q2 2026, from $189.7 million in the prior quarter.
- Over five years, Accumulated Expenses peaked at $198.8 million in Q2 2026 and troughed at $140.2 million in Q1 2022.
- A 5-year average of $165.3 million and a median of $164.8 million in 2023 frame the typical range for Accumulated Expenses.
- The largest YoY upside for Accumulated Expenses was 20.01% in 2022 against a maximum downside of 16.04% in 2022.
- A 5-year view of Accumulated Expenses shows it stood at $151.7 million in 2022, then increased by 1.72% to $154.3 million in 2023, then rose by 9.35% to $168.7 million in 2024, then declined by 4.51% to $161.1 million in 2025, then climbed by 23.43% to $198.8 million in 2026.
- Per Business Quant data, the three most recent Accumulated Expenses figures were $198.8 million in Q2 2026, $189.7 million in Q1 2026, and $161.1 million in Q4 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Haleon | 43.91 Bn | 42.95 Bn | - |
| 2 | Teva Pharmaceutical Industries | 42.98 Bn | 39.32 Bn | 2.15 Bn |
| 3 | Zoetis | 31.53 Bn | 29.86 Bn | 1.05 Bn |
| 4 | Takeda Pharmaceutical | 28.61 Bn | 22.81 Bn | 5.10 Bn |
| 5 | United Therapeutics | 22.16 Bn | 19.49 Bn | 683.80 Mn |
| 6 | Viatris | 18.74 Bn | 17.85 Bn | 1.46 Bn |
| 7 | Neurocrine Biosciences | 15.51 Bn | 15.12 Bn | 935.80 Mn |
| 8 | Elanco Animal Health | 11.76 Bn | 11.23 Bn | 798.00 Mn |
| 9 | Dr Reddys Laboratories | 10.12 Bn | 9.95 Bn | - |
| 10 | Supernus Pharmaceuticals | 2.75 Bn | 2.37 Bn | 185.39 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 198.84 Mn |
| Mar 31, 2026 | 101.24 Mn |
| Dec 31, 2025 | 107.80 Mn |
| Sep 30, 2025 | 184.46 Mn |
| Jun 30, 2025 | 77.74 Mn |
| Mar 31, 2025 | 170.13 Mn |
| Dec 31, 2024 | 76.35 Mn |
| Sep 30, 2024 | 169.12 Mn |
| Jun 30, 2024 | 82.61 Mn |
| Mar 31, 2024 | 167.23 Mn |
| Dec 31, 2023 | 79.57 Mn |
| Sep 30, 2023 | 162.47 Mn |
| Jun 30, 2023 | 83.04 Mn |
| Mar 31, 2023 | 147.85 Mn |
| Dec 31, 2022 | 96.34 Mn |
| Sep 30, 2022 | 110.30 Mn |
| Jun 30, 2022 | 145.76 Mn |
| Mar 31, 2022 | 140.18 Mn |
| Dec 31, 2021 | 117.68 Mn |
| Sep 30, 2021 | 132.05 Mn |